Ionis Pharmaceuticals Inc Collaboration with AstraZeneca - Eplontersen Development and Commercialization Update Webcast Transcript
Good morning, and welcome to Ionis' conference call to discuss the eplontersen development and commercialization update. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Jennifer Capuzelo, Investor Relations to lead off the call. Please begin.
Thank you, Tom. Hello, and thank you for joining us this morning for a discussion about our collaboration agreement with AstraZeneca for eplontersen. Before we begin, I encourage everyone to review the press release, Ionis issued last night, which outlines the details of this agreement.
During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional details.
Joining me on today's call are Brett Monia, Chief Executive Officer; Onaiza Cadoret-Manier, Chief Corporate Development and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |